Hey Neurohacker,

Thank you for tuning in this week! Do you have 1 minute? Give me feedback on The Neurocircuit.

✦ This Week's Partner: Forward Future

Neurotechnology News | March 28 – April 3, 2026

Let's cut through the noise.

This week, a Nature paper rewrote a foundational assumption about the brain signal at the core of most ECoG-based BCIs, while Science Corporation moved its living-neuron interface closer to clinic with a marquee surgical hire. Meanwhile, a coalition of 150+ organizations told Congress that the public R&D engine powering all of this faces a structural funding cliff in months. Bottom line: the clinical translation pipeline is accelerating precisely as its upstream funding erodes.

⚡ Signal of the Week

A Northwestern team used a BMI to prove that high gamma activity — one of the most widely used signals in neuroscience and BCIs — does not primarily reflect local neuronal firing.

Published April 1 in Nature, the study trained non-human primates to decouple local spiking from high gamma band activity (HGA, 70–300 Hz) recorded on the same electrode. Subjects succeeded within minutes, falsifying the dominant hypothesis that HGA represents summed local spikes. Instead, HGA correlates with synchronous co-firing of neurons distributed across millimetres of cortex, suggesting it arises from summed postsynaptic potentials rather than nearby action potentials.

This stands above every other story this week because its implications are immediate and practical for anyone building or interpreting BCI systems. HGA-based decoders are deployed across ECoG BCIs, intraoperative brain mapping, and hundreds of published neuroimaging studies. If HGA is not a localized motor-intent proxy but a distributed network-state signal, then spatial specificity claims in existing decoders are wrong, and the relative stability of HGA over time — long observed but poorly explained — finally has a mechanistic account. It is also good news for decoder robustness; it means HGA integrates across a wider population, which is exactly why it is harder to perturb than single-unit recordings. This is the paper every BCI engineer should read this week, and it is a direct call to revisit published decoder validation studies that rely on HGA localization assumptions.

🟢 HGA Dissociated from Local Spiking — Foundational BCI Signal Reinterpreted

Published: April 1, 2026
Read more ➡️ Northwestern Feinberg Medicine / Nature

Using a purpose-built brain–machine interface in non-human primates, Northwestern researchers demonstrated that cortical HGA (70–300 Hz) arises primarily from summed postsynaptic potentials of neurons distributed across millimetres of cortex — not from summed local action potentials near the recording electrode. Subjects learned to decouple spiking rates from HGA on a single electrode within minutes, directly falsifying the most widely held hypothesis about HGA's biophysical origin.

💡 Big Picture: BCI decoders and intraoperative brain mapping studies that treat HGA as a localized motor-intent signal are built on an incorrect spatial model — this shifts HGA from a "who fired here" signal to a "what is the network state" signal, which changes both how decoders should be trained and how published localization results should be interpreted.

Published: March 31, 2026
Read more ➡️ BusinessWire / science.xyz

Science Corporation appointed Murat Günel, MD — Sterling Professor of Neurosurgery and Chair of Neurosurgery at Yale School of Medicine, and Neurosurgeon-in-Chief of Yale New Haven Health System — as Medical Director for Brain-Computer Interfaces, with responsibility for developing the clinical and surgical programs for its Biohybrid project. The appointment follows Science's $230 million Series C close; Biohybrid uses living neurons grown on a scaffold as the neural interface, rather than rigid silicon electrodes, aiming for higher bandwidth and reduced inflammatory response.

💡 Big Picture: Recruiting the chair of Yale neurosurgery is not a PR move — it is the specific hire you make when you need to design a first-in-human surgical protocol for a device category that has no established implantation procedure, because the "electrode" is a biological tissue construct rather than metal or silicon.

Published: March 30, 2026
Read more ➡️ MassDevice / PR Newswire

BrainsWay completed a $6M milestone-based investment in Neurolief, triggered by Neurolief's FDA Premarket Approval (PMA) for Proliv™Rx — the first and only at-home, physician-directed brain neuromodulation therapy for major depressive disorder (MDD) in adults who failed at least one antidepressant — and Neurolief simultaneously announced inclusion on the Veterans Affairs Federal Supply Schedule, opening a direct commercial pathway into the VA health system. The MOOD RCT supporting the PMA showed a 21.3% remission rate vs. 6.0% for sham (p=0.027) at 8 weeks and 32% remission rate in the open-label phase.

💡 Big Picture: VA Federal Supply Schedule entry is the commercial equivalent of a hospital formulary addition — it removes a procurement barrier for the largest integrated health system in the US and creates a replicable template for payer adoption that the broader neuromodulation-at-home category did not previously have.

Published: ~March 29–30, 2026
Read more ➡️ The Transmitter / STAT News / Understanding the BRAIN Initiative Budget | BRAIN Initiative

The American Brain Coalition, coordinating 150+ organizations, sent a formal letter to Congress on March 27 requesting ~$500M in sustained base funding for the BRAIN Initiative — necessary because the 21st Century Cures Act supplemental funding expires after FY2026, which would drop the program's budget from $429M (FY2026) to ~$230M base, an effective ~46% cut. The number of neuroscience grants awarded already fell 37% year-over-year under current multiyear funding policy; the American Brain Coalition plans a Capitol Hill briefing on April 22 to demonstrate clinical impact of BRAIN-funded research.

💡 Big Picture: The BRAIN Initiative has been the primary funder of open electrode technology, circuit-mapping tools, and neural interface standards that commercial BCI companies build on top of — a ~$200M annual cut at the basic research layer removes the tool-development scaffolding that de-risks private device R&D, creating a translational gap that venture capital cannot fill because it has no return model for pre-competitive infrastructure.

Who builds the next generation of BCI infrastructure if public funding contracts by $200M per year?

This week's BRAIN Initiative letter makes the systems dependency explicit: every commercial BCI milestone announced in the past year — closed-loop neuromodulation, high-density electrode arrays, neural decoder algorithms — rests on a base of federally funded tool development that is now at risk. The tension is structural, not political: the Cures Act was always designed to sunset in 2026, and no replacement funding mechanism has been authorized. The open question is whether the neurotech industry — which just absorbed hundreds of millions in venture capital this month alone — has any incentive to fund pre-competitive research infrastructure it currently gets for free, or whether the next decade of translation simply becomes narrower, slower, and less diverse as the public layer contracts.

AI is moving faster than any other technology cycle in history. New models. New tools. New claims. New noise.

Most people feel like they’re behind. But the people that don’t, aren’t smarter. They’re just better informed.

Forward Future is a daily news briefing for people who want clarity, not hype. In one concise newsletter each day, you’ll get the most important AI and tech developments, learn why they matter, and what they signal about what’s coming next.

We cover real product launches, model updates, policy shifts, and industry moves shaping how AI actually gets built, adopted, and regulated. Written for operators, builders, leaders, and anyone who wants to sound sharp when AI comes up in the meeting.

It takes about five minutes to read, but the edge lasts all day.

Sign Up. Look Smart.